Diane Reidy-Lagunes, MD
2017 was an important year for patients with neuroendocrine tumors (NETs). Diane Reidy-Lagunes, MD, said the phase III NETTER-1 trial comparing Lutathera (lutetium [177Lu] oxodotreotide) plus best supportive care versus octreotide (Sandostatin) LAR was a significant development in the treatment of patients with advanced midgut NETs.
on Gastrointestinal Cancers, Reidy-Lagunes, a medical oncologist at Memorial Sloan Kettering Cancer Center, discussed ongoing developments for the treatment of patients with gastrointestinal (GI) and pancreatic NETs.
OncLive: Please provide an overview of your presentation on GI and pancreatic NETs.
I gave an overview on the treatment of NETs, which is changing quickly, but also how you diagnose and define the patient and develop personalized medicine.
... to read the full story